Neil B Newman1, Rebecca A Moss2,3, Nell Maloney-Patel4, Kristen Donohue4, Teresa V Brown2, Michael J Nissenblatt5, Shou-En Lu6, Salma K Jabbour1. 1. Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA. 2. Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA. 3. Bristol-Myers Squibb, Lawrence, NJ, USA. 4. Department of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA. 5. Regional Cancer Care Associates, East Brunswick, NJ, USA. 6. Rutgers School of Public Health, Division of Biometrics, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.
Abstract
BACKGROUND: This study seeks to quantify and compare bone marrow tolerance during postoperative chemotherapy therapy between rectal cancer vs. colon cancer patients. During rectal cancer treatment, patients receive neoadjuvant chemoradiation (CRT) irradiation which can exacerbate the hematologic toxicity (HT) via incidental irradiation of the pelvic bone marrow (PBM) during myelosuppressive postoperative chemotherapy. In contrast, colon cancer patients receive the same postoperative myelosuppressive chemotherapy but do not routinely receive preoperative chemoradiation therapy. This comparison will help elucidate the lasting myelosuppressive effects of incidental pelvic bone marrow (PBM) irradiation on rectal cancer patients during neoadjuvant preoperative chemoradiation therapy. METHODS: Rectal cancer patients treated with preoperative CRT followed by postoperative 5-Fluorouracil and oxaliplatin (OxF) chemotherapy (n=35) were compared to colon cancer patients who received only postoperative OxF chemotherapy (n=42). End points were ≥ grade 3 hematologic toxicity (HT3) or hematologic event (HE) defined as ≥ grade 2 HT and a dose reduction in OxF. Wilcoxon rank sum test tested continuous variables and Chi-squared test measured differences in categorical variables. HT3 and HE probability during postoperative chemotherapy was estimated with Kaplan-Meier curves and Cox regression analysis. RESULTS: During OxF chemotherapy, 40.0% (n=14) of rectal cancer patients experienced HT3 compared to 26.1% (n=11) of colon cancer patients (P=0.4). HE was experienced by 48% (n=17) of rectal cancer patients compared to 36% (n=15) of colon cancer patients (P=0.36). Rectal cancer patients were likelier to experience HT3 on multivariable cox regression analysis, controlling for several clinical covariates, with a hazard ratio (HR) of 2.49, [(95% CI: 1.02-6.02), P=0.045] than colon cancer patients. While rectal cancer patients were more likely to experience HE than colon cancer patients on multivariable Cox regression analysis with a HR of 1.8 (95% CI: 0.95-3.75), this only trended in statistical significance, P=0.07. CONCLUSIONS: Rectal cancer patients are more likely than colon cancer patients to experience hematologic toxicities impacting the tolerance of standard of care chemotherapeutics during adjuvant therapy. Focused PBM sparing during radiation therapy for rectal cancer patients may improve tolerance of myelosuppressive chemotherapeutic agents delivered in the postoperative setting.
BACKGROUND: This study seeks to quantify and compare bone marrow tolerance during postoperative chemotherapy therapy between rectal cancer vs. colon cancerpatients. During rectal cancer treatment, patients receive neoadjuvant chemoradiation (CRT) irradiation which can exacerbate the hematologic toxicity (HT) via incidental irradiation of the pelvic bone marrow (PBM) during myelosuppressive postoperative chemotherapy. In contrast, colon cancerpatients receive the same postoperative myelosuppressive chemotherapy but do not routinely receive preoperative chemoradiation therapy. This comparison will help elucidate the lasting myelosuppressive effects of incidental pelvic bone marrow (PBM) irradiation on rectal cancerpatients during neoadjuvant preoperative chemoradiation therapy. METHODS:Rectal cancerpatients treated with preoperative CRT followed by postoperative 5-Fluorouracil and oxaliplatin (OxF) chemotherapy (n=35) were compared to colon cancerpatients who received only postoperative OxF chemotherapy (n=42). End points were ≥ grade 3 hematologic toxicity (HT3) or hematologic event (HE) defined as ≥ grade 2 HT and a dose reduction in OxF. Wilcoxon rank sum test tested continuous variables and Chi-squared test measured differences in categorical variables. HT3 and HE probability during postoperative chemotherapy was estimated with Kaplan-Meier curves and Cox regression analysis. RESULTS: During OxF chemotherapy, 40.0% (n=14) of rectal cancerpatients experienced HT3 compared to 26.1% (n=11) of colon cancerpatients (P=0.4). HE was experienced by 48% (n=17) of rectal cancerpatients compared to 36% (n=15) of colon cancerpatients (P=0.36). Rectal cancerpatients were likelier to experience HT3 on multivariable cox regression analysis, controlling for several clinical covariates, with a hazard ratio (HR) of 2.49, [(95% CI: 1.02-6.02), P=0.045] than colon cancerpatients. While rectal cancerpatients were more likely to experience HE than colon cancerpatients on multivariable Cox regression analysis with a HR of 1.8 (95% CI: 0.95-3.75), this only trended in statistical significance, P=0.07. CONCLUSIONS:Rectal cancerpatients are more likely than colon cancerpatients to experience hematologic toxicities impacting the tolerance of standard of care chemotherapeutics during adjuvant therapy. Focused PBM sparing during radiation therapy for rectal cancerpatients may improve tolerance of myelosuppressive chemotherapeutic agents delivered in the postoperative setting.
Entities:
Keywords:
Hematologic toxicity (HT); bone marrow; chemoradiation; colon cancer; rectal cancer
Authors: Carmen J Allegra; Greg Yothers; Michael J O'Connell; Robert W Beart; Timothy F Wozniak; Henry C Pitot; Anthony F Shields; Jerome C Landry; David P Ryan; Amit Arora; Lisa S Evans; Nathan Bahary; Gamini Soori; Janice F Eakle; John M Robertson; Dennis F Moore; Michael R Mullane; Benjamin T Marchello; Patrick J Ward; Saima Sharif; Mark S Roh; Norman Wolmark Journal: J Natl Cancer Inst Date: 2015-09-14 Impact factor: 13.506
Authors: Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544
Authors: Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544
Authors: W Scheithauer; J McKendrick; S Begbie; M Borner; W I Burns; H A Burris; J Cassidy; D Jodrell; P Koralewski; E L Levine; N Marschner; J Maroun; P Garcia-Alfonso; J Tujakowski; G Van Hazel; A Wong; J Zaluski; C Twelves Journal: Ann Oncol Date: 2003-12 Impact factor: 32.976
Authors: Neil B Newman; Manpreet K Sidhu; Rekha Baby; Rebecca A Moss; Michael J Nissenblatt; Ting Chen; Shou-En Lu; Salma K Jabbour Journal: Int J Radiat Oncol Biol Phys Date: 2016-01-05 Impact factor: 7.038
Authors: Salma K Jabbour; Shyamal Patel; Joseph M Herman; Aaron Wild; Suneel N Nagda; Taghrid Altoos; Ahmet Tunceroglu; Nilofer Azad; Susan Gearheart; Rebecca A Moss; Elizabeth Poplin; Lydia L Levinson; Ravi A Chandra; Dirk F Moore; Chunxia Chen; Bruce G Haffty; Richard Tuli Journal: Int J Surg Oncol Date: 2012-08-13
Authors: Zeta Chow; Tong Gan; Quan Chen; Bin Huang; Nancy Schoenberg; Mark Dignan; B Mark Evers; Avinash S Bhakta Journal: J Am Coll Surg Date: 2020-02-13 Impact factor: 6.532